Related Products
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
GLOW 70mg
70mg
Related Research News
Cenna Biosciences Gets FDA Clearance for Phase 1 Trial of Alzheimer's Peptide 8M2D
Cenna Biosciences has received FDA clearance to begin a Phase 1a/1b clinical trial for 8M2D, a first-in-class peptide designed to stop amyloid production in Alzheimer's disease. The announcement was made on June 17, 2026, marking a regulatory milestone for the experimental therapy.
FDA Targets Telehealth Companies Over Compounded Semaglutide Claims
The US FDA sent 25 warning letters to telehealth companies regarding misleading claims about compounded weight-loss drugs, including semaglutide. This action highlights regulatory concerns over the promotion of unapproved versions of drugs like Ozempic and Wegovy. The news carries implications for peptide researchers and the broader industry.
Cenna Biosciences Gets FDA Nod for Alzheimer's Peptide Trial
Cenna Biosciences has received FDA clearance to begin a Phase 1a/1b clinical trial of 8M2D, a first-in-class peptide designed to stop amyloid production in Alzheimer's disease. The regulatory green light marks a key step toward testing the novel therapeutic in humans.